or Try an Advanced Search...

    Technical Analysis for ERAS - Erasca, Inc

    Grade Last Price % Change Price Change
    C 2.00 -7.13% -0.15
    ERAS closed down 1.38 percent on Wednesday, May 8, 2024, on 58 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. It was able to find support at its 50 day moving average. The stock fell below its 200 day moving average, damaging its long-term outlook by crossing under that critical trendline. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or a pulls back.
    Earnings due: May 9
    *** please verify all earnings dates ***
    2 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent Down Down Down
    Historical ERAS trend table...
    Date Alert Name Type % Chg
    Fell Below 200 DMA Bearish -7.13%
    Stochastic Sell Signal Bearish -7.13%
    50 DMA Support Bullish -7.13%
    NR7 Range Contraction -7.13%
    Overbought Stochastic Strength -7.13%
    200 DMA Support Bullish -8.41%
    Wide Bands Range Expansion -8.41%
    Overbought Stochastic Strength -8.41%
    50 DMA Support Bullish -9.66%
    Crossed Above 200 DMA Bullish -9.66%
    Older End-of-Day Signals for ERAS ...

       Recent Intraday Alerts

    Alert Time
    20 DMA Support 18 minutes ago
    Fell Below 20 DMA 42 minutes ago
    Down 5% about 1 hour ago
    Down 1 ATR about 1 hour ago
    Down 3% about 2 hours ago
    View Earlier Intraday Alerts

    Get a Trading Sidekick!

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Get Started for Free!
    Configure default chart indicators
    ERAS Chart by TradingView
    Basic chart:

    Profile

    Erasca, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Its lead candidates include ERAS-007, an oral inhibitor of ERK1/2 for the treatment of NSCLC, colorectal cancer, and acute myeloid leukemia; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. The company was incorporated in 2018 and is headquartered in San Diego, California.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Biopharmaceutical Cancer Acute Myeloid Leukemia Colorectal Cancer Enzymes Tyrosine Kinase Receptors Oncogenes NSCLC Non Small Cell Lung Carcinoma Metastatic Solid Tumors Bemcentinib Ras Gtpase Ptpn11

    Is ERAS a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 1 bullish, 1 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    May 8 Erasca Reports First Quarter 2024 Business Updates and Financial Results
    May 7 Erasca to Present at the Bank of America Health Care Conference
    Apr 24 Erasca Announces Three Presentations at the 2024 ASCO Annual Meeting
    Apr 23 Erasca (ERAS) Upgraded to Strong Buy: What Does It Mean for the Stock?
    Apr 16 Institutional investors may adopt severe steps after Erasca, Inc.'s (NASDAQ:ERAS) latest 11% drop adds to a year losses
    Apr 1 Erasca, Inc. (NASDAQ:ERAS) Q4 2023 Earnings Call Transcript
    Mar 29 Erasca, Inc. (ERAS) R&D Update Call and Q4 2023 Earnings Call Transcript
    Mar 29 Erasca Inc (ERAS) Aligns with EPS Projections, Reveals Robust Balance Sheet and Key Clinical ...
    Mar 28 Erasca to get $45M funding via private placement
    Mar 28 Erasca Announces $45 Million Oversubscribed Private Placement Financing
    See more ERAS news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 3.375
    52 Week Low 1.51
    Average Volume 706,188
    200-Day Moving Average 2.17
    50-Day Moving Average 2.11
    20-Day Moving Average 2.01
    10-Day Moving Average 2.07
    Average True Range 0.13
    RSI (14) 56.33
    ADX 21.51
    +DI 29.25
    -DI 17.23
    Chandelier Exit (Long, 3 ATRs) 2.05
    Chandelier Exit (Short, 3 ATRs) 2.13
    Upper Bollinger Bands 2.30
    Lower Bollinger Band 1.71
    Percent B (%b) 0.74
    BandWidth 29.32
    MACD Line 0.02
    MACD Signal Line -0.01
    MACD Histogram 0.0327
    Fundamentals Value
    Market Cap 324.84 Million
    Num Shares 151 Million
    EPS -1.73
    Price-to-Earnings (P/E) Ratio -1.24
    Price-to-Sales 0.00
    Price-to-Book 0.78
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 2.27
    Resistance 3 (R3) 2.27 2.22 2.25
    Resistance 2 (R2) 2.22 2.19 2.23 2.24
    Resistance 1 (R1) 2.19 2.17 2.17 2.19 2.24
    Pivot Point 2.14 2.14 2.13 2.15 2.14
    Support 1 (S1) 2.11 2.11 2.09 2.11 2.06
    Support 2 (S2) 2.06 2.09 2.07 2.06
    Support 3 (S3) 2.03 2.06 2.05
    Support 4 (S4) 2.03